search
Back to results

Treatment of Metabolic Alkalosis With Acetazolamide. Effect on the Length of Mechanical Ventilation. (TRAMA)

Primary Purpose

Pulmonary Disease, Chronic Obstructive, Obesity Hypoventilation Syndrome, Metabolic Alkalosis

Status
Completed
Phase
Phase 3
Locations
Spain
Study Type
Interventional
Intervention
Acetazolamide
Placebo
Sponsored by
Hospital Son Llatzer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pulmonary Disease, Chronic Obstructive focused on measuring Pulmonary Disease, Chronic Obstructive, Obesity Hypoventilation Syndrome, Alkalosis, Respiration, Artificial, Acetazolamide, Intensive care, Adult

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with COPD or obesity hypoventilation syndrome on invasive mechanical ventilation during less than 72 h with metabolic alkalosis, defined as a pH > 7.35 and actual bicarbonate > 28 mmol/L, and with potassium plasmatic levels >= 4 mEq/L.

Exclusion Criteria:

  • Postoperative patients.
  • Previous psychiatric disease.
  • Epilepsy.
  • Pregnancy.
  • Hepatic cirrhosis.
  • Sulfonamide or acetazolamide allergy.
  • Plasmatic creatinine > 2.5 mg/dL or creatinine clearance < 20 mL/min or continuous renal replacement techniques.
  • Intolerance to enteral feeding.
  • Administration in the previous 72 h of bicarbonate or acetazolamide.
  • Terminal disease.

Sites / Locations

  • Fundació Hospital Asil de Granollers
  • Hospital de Sant Joan Despí Moisès Broggi
  • Hospital Universitario Infanta Leonor
  • Fundación Jiménez Díaz
  • Hospital de Manacor
  • Hospital Son Espases
  • Hospital Son Llàtzer
  • Hospital de la Santa Creu i Sant Pau

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Acetazolamide

placebo

Arm Description

Outcomes

Primary Outcome Measures

Length of mechanical ventilation

Secondary Outcome Measures

Length of intensive care unit stay
All cause hospital mortality
Alive or dead status will be recorded at the end of hospital stay
Complications associated to the treatment
Plasma and urine analysis will be performed to detect alteration in electrolites or renal function.

Full Information

First Posted
December 20, 2011
Last Updated
March 16, 2015
Sponsor
Hospital Son Llatzer
search

1. Study Identification

Unique Protocol Identification Number
NCT01499485
Brief Title
Treatment of Metabolic Alkalosis With Acetazolamide. Effect on the Length of Mechanical Ventilation.
Acronym
TRAMA
Official Title
Effects of Acetazolamide on the Duration of Mechanical Ventilation in Patients With Metabolic Alkalosis. Phase III Multicenter Double-blinded Clinical Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
February 2015 (Actual)
Study Completion Date
February 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital Son Llatzer

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to analyze whether the treatment of metabolic alkalosis with acetazolamide in intubated patients with chronic obstructive pulmonary disease (COPD) or with obesity hypoventilation syndrome (OHS) reduces the length of mechanical ventilation (MV).
Detailed Description
Metabolic alkalosis (MA) may reduce central respiratory drive, cardiac output and worsen oxygenation, leading to a delay in weaning from MV. Acetazolamide is a carbonic anhydrase inhibitor that is able to correct MA and to stimulate respiratory drive. There is a paucity of studies on the outcome of patients with MA under MV treated with acetazolamide. The primary objective of our study is to analyze whether the treatment of MA with acetazolamide in intubated patients with COPD or with OHS reduces the length of MV, reduces the length of ICU stay or ICU mortality. Complications associated with acetazolamide treatment will be also analyzed. Phase III double-blinded trial, with COPD or OHS patients under MV who have pH > 7,35 and bicarbonate > 28 mEq/L. Patients will be randomized to receive 500 mg of acetazolamide or placebo. According to arterial blood gas analysis (ABGA) values treatment administration will be evaluated daily until extubation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Disease, Chronic Obstructive, Obesity Hypoventilation Syndrome, Metabolic Alkalosis
Keywords
Pulmonary Disease, Chronic Obstructive, Obesity Hypoventilation Syndrome, Alkalosis, Respiration, Artificial, Acetazolamide, Intensive care, Adult

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
140 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Acetazolamide
Arm Type
Experimental
Arm Title
placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Acetazolamide
Other Intervention Name(s)
Edemox
Intervention Description
Daily morning ABGA: If actual bicarbonate > 26 mmol/L and pH > 7.35: administration of enteral capsule of acetazolamide 500 mg . If actual bicarbonate > 26 mmol/L and pH <= 7.35, increase minute ventilation to reach pH > 7.35 and then administer enteral capsule of acetazolamide 500 mg. If actual bicarbonate <= 26 mmol/L: omit treatment that day.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Daily morning ABGA: If actual bicarbonate > 26 mmol/L and pH > 7.35: administration of enteral capsule of placebo. If actual bicarbonate > 26 mmol/L and pH <= 7.35, increase minute ventilation to reach pH > 7.35 and then administer enteral capsule of placebo. If actual bicarbonate <= 26 mmol/L: omit treatment that day.
Primary Outcome Measure Information:
Title
Length of mechanical ventilation
Time Frame
From intubation date to extubation date, an expected average of 1 week
Secondary Outcome Measure Information:
Title
Length of intensive care unit stay
Time Frame
The duration of ICU stay, an expected average less than 2 weeks
Title
All cause hospital mortality
Description
Alive or dead status will be recorded at the end of hospital stay
Time Frame
Participants will be followed for the duration of hospital stay, an expected average of 3 weeks
Title
Complications associated to the treatment
Description
Plasma and urine analysis will be performed to detect alteration in electrolites or renal function.
Time Frame
During the mechanical ventilation period, an expected average of 1 week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with COPD or obesity hypoventilation syndrome on invasive mechanical ventilation during less than 72 h with metabolic alkalosis, defined as a pH > 7.35 and actual bicarbonate > 28 mmol/L, and with potassium plasmatic levels >= 4 mEq/L. Exclusion Criteria: Postoperative patients. Previous psychiatric disease. Epilepsy. Pregnancy. Hepatic cirrhosis. Sulfonamide or acetazolamide allergy. Plasmatic creatinine > 2.5 mg/dL or creatinine clearance < 20 mL/min or continuous renal replacement techniques. Intolerance to enteral feeding. Administration in the previous 72 h of bicarbonate or acetazolamide. Terminal disease.
Facility Information:
Facility Name
Fundació Hospital Asil de Granollers
City
Granollers
State/Province
Barcelona
ZIP/Postal Code
08402
Country
Spain
Facility Name
Hospital de Sant Joan Despí Moisès Broggi
City
Sant Joan Despí
State/Province
Barcelona
ZIP/Postal Code
08970
Country
Spain
Facility Name
Hospital Universitario Infanta Leonor
City
Madrid
State/Province
Comunidad de Madrid
ZIP/Postal Code
28031
Country
Spain
Facility Name
Fundación Jiménez Díaz
City
Madrid
State/Province
Comunidad de Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital de Manacor
City
Manacor
State/Province
Illes Balears
ZIP/Postal Code
07500
Country
Spain
Facility Name
Hospital Son Espases
City
Palma de Mallorca
State/Province
Illes Balears
ZIP/Postal Code
07010
Country
Spain
Facility Name
Hospital Son Llàtzer
City
Palma de Mallorca
State/Province
Illes Balears
ZIP/Postal Code
07198
Country
Spain
Facility Name
Hospital de la Santa Creu i Sant Pau
City
Barcelona
ZIP/Postal Code
08025
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
20217045
Citation
Faisy C, Mokline A, Sanchez O, Tadie JM, Fagon JY. Effectiveness of acetazolamide for reversal of metabolic alkalosis in weaning COPD patients from mechanical ventilation. Intensive Care Med. 2010 May;36(5):859-63. doi: 10.1007/s00134-010-1795-7. Epub 2010 Mar 9.
Results Reference
background
PubMed Identifier
20979670
Citation
Raurich JM, Rialp G, Ibanez J, Llompart-Pou JA, Ayestaran I. Hypercapnic respiratory failure in obesity-hypoventilation syndrome: CO(2) response and acetazolamide treatment effects. Respir Care. 2010 Nov;55(11):1442-8.
Results Reference
background
PubMed Identifier
10446816
Citation
Mazur JE, Devlin JW, Peters MJ, Jankowski MA, Iannuzzi MC, Zarowitz BJ. Single versus multiple doses of acetazolamide for metabolic alkalosis in critically ill medical patients: a randomized, double-blind trial. Crit Care Med. 1999 Jul;27(7):1257-61. doi: 10.1097/00003246-199907000-00004.
Results Reference
background
PubMed Identifier
19938966
Citation
Banga A, Khilnani GC. Post-hypercapnic alkalosis is associated with ventilator dependence and increased ICU stay. COPD. 2009 Dec;6(6):437-40. doi: 10.3109/15412550903341448.
Results Reference
background
PubMed Identifier
16420662
Citation
Moviat M, Pickkers P, van der Voort PH, van der Hoeven JG. Acetazolamide-mediated decrease in strong ion difference accounts for the correction of metabolic alkalosis in critically ill patients. Crit Care. 2006 Feb;10(1):R14. doi: 10.1186/cc3970.
Results Reference
background
PubMed Identifier
28286047
Citation
Rialp Cervera G, Raurich Puigdevall JM, Moran Chorro I, Martin Delgado MC, Heras la Calle G, Mas Serra A, Vallverdu Perapoch I. Effects of early administration of acetazolamide on the duration of mechanical ventilation in patients with chronic obstructive pulmonary disease or obesity-hypoventilation syndrome with metabolic alkalosis. A randomized trial. Pulm Pharmacol Ther. 2017 Jun;44:30-37. doi: 10.1016/j.pupt.2017.03.002. Epub 2017 Mar 7.
Results Reference
derived

Learn more about this trial

Treatment of Metabolic Alkalosis With Acetazolamide. Effect on the Length of Mechanical Ventilation.

We'll reach out to this number within 24 hrs